401573-23-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-acetamidobenzylcarbamate is used as a pharmaceutical intermediate for the synthesis of various pharmaceutical compounds. It plays a crucial role in the development of new drugs and medicines, contributing to the advancement of healthcare and treatment options.
Used in Research and Development:
In the field of research and development, tert-butyl 4-acetamidobenzylcarbamate serves as a building block for the creation of innovative pharmaceutical compounds. Its utilization in this area aids in the discovery and improvement of drugs, enhancing the overall effectiveness and safety of medications.

Upstream product

• 1228693-04-6 C₂₅H₂₅F₁₇N₂O₄ 
• 4403-71-8 (4-aminomethyl)aniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-36-5 acetyl chloride 
• 94838-55-8 tert-butyl (4-aminobenzyl)carbamate 

Downstream Products

• 25027-73-0 (4-acetamidophenyl)methanammonium chloride 

Relevant academic research and scientific papers

INHIBITORS OF THE MENIN-MLL INTERACTION

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Synthesis and application of a new fluorous-tagged ammonia equivalent

A novel fluorous-tagged ammonia equivalent has been developed. It is based on a nitrogen-oxygen bond, which can be cleaved in a traceless manner by a molybdenum complex or samarium diiodide. The application in the synthesis of ureas, amides, sulfonamides, and carbamates is described. The scope of the fluo-rous N-O linker is exemplified by the synthesis of itopride, a drug used for the treatment of functional dyspepsia. Itopride was synthesized with the aid of fluorous purification methods and the product was isolated in good overall yield, with high purity.

Improved syntheses of 5′- S -(2-Aminoethyl)-6- N -(4-nitrobenzyl)- 5′-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: Analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor

5′-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), 5′-S-(2-acetamidoethyl)-6-N-[(4-substituted)benzyl]-5′- thioadenosine analogues, 5′-S-[2-(6-aminohexanamido)]ethyl-6-N-(4- nitrobenzyl)-5′-thioadenosine (SAHENTA), and related compounds we

N-(3-acyloxy-2-benzylpropyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues: Novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor

Isosteric replacement of the phenolic hydroxyl group in potent vanilloid receptor (VR1) agonists with the alkylsulfonamido group provides a series of compounds which are effective antagonists to the action of the capsaicin on rat VR1 heterologously expressed in Chinese hamster ovary (CHO) cells. In particular, compound 61, N-[2-(3,4-dimethylbenzyl)-3-pivaloyloxypropyl]-N′-[3-fluoro-4- (methylsulfonylamino)benzyl]thiourea was a full antagonist against capsaicin, displayed a Ki value of 7.8 nM (compared to 520 nM for capsazepine and 4 nM for 5-iodoRTX), and showed excellent analgesic activity in mice. Structure-activity analysis of the influence of modifications in the A- and C-regions of 4-methylsulfonamide ligands on VR1 agonism/antagonism indicated that 3-fluoro substitution in the A-region and a 4-tert-butylbenzyl moiety in the C-region favored antagonism, whereas a 3-methoxy group in the A-region and 3-acyloxy2-benzylpropyl moieties in the C-region favored agonism.